公开(公告)号：WO2003022265A1

公开(公告)日：2003-03-20

申请号：PCT/KR2001/001614

申请日：2001-09-26

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  DAEHWA PHARM. CO., LTD. ,  CHUNG, Hesson ,  JEONG, Seo, Young ,  KWON, Ick, Chan ,  PARK, Jae, Hyung ,  CHUNG, Jin, Wook ,  KIM, Young, Man ,  LEE, In-Hyun

Inventor： CHUNG, Hesson ,  JEONG, Seo, Young ,  KWON, Ick, Chan ,  PARK, Jae, Hyung ,  CHUNG, Jin, Wook ,  KIM, Young, Man ,  LEE, In-Hyun

IPC: A61K31/335

CPC classification number: A61K49/0452 ,  A61K9/0019 ,  A61K31/337 ,  A61K47/44

Abstract: Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof solubilizing paclitaxel in an oily contrast medium. The composition of the present invention solubilizes paclitaxel and has an advantage of delivering anticancer drug to the target cells by chemoembolization since it is possible to visualize the blood vessel during the chemoembolization process.

Abstract translation: 油性紫杉醇组合物和化疗栓塞制剂及其在油性造影剂中增溶紫杉醇的制备方法。 本发明的组合物溶解紫杉醇，并且具有通过化学栓塞将抗癌药物递送至靶细胞的优点，因为在化学栓塞过程中可以使血管可视化。

公开(公告)号：WO2002064166A1

公开(公告)日：2002-08-22

申请号：PCT/KR2002/000206

申请日：2002-02-08

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  CHUNG, Hesson

Inventor： JEONG, Seo-Young ,  KWON, Ick-Chan ,  CHUNG, Hesson

IPC: A61K47/44

CPC classification number: A61K9/0014 ,  A61K9/0019 ,  A61K47/44

Abstract: The present invention relates to compositions and formulations to enhance bioavailability of bioactive materials and preparation method thereof. More particularly, the present invention relates to a composition comprising at least one monoglyceride, at least one emulsifier, organic solvents and aqueous solution and a liquid and powder formulation prepared by adding bioactive material with a low bioavailabiliy to enhance bioavailability of bioactive materials and to acquire high encapsulation efficiency of the bioactive material and high storage stability for a long period of time and preparation method thereof.

Abstract translation: 本发明涉及提高生物活性物质生物利用度的组合物和制剂及其制备方法。 更具体地说，本发明涉及包含至少一种单酸甘油酯，至少一种乳化剂，有机溶剂和水溶液的组合物，以及通过加入具有低生物利用度的生物活性物质以提高生物活性物质的生物利用度并获得的液体和粉末制剂 生物活性材料的高封装效率和长时间的高储存稳定性及其制备方法。

公开(公告)号：WO2004009076A1

公开(公告)日：2004-01-29

申请号：PCT/KR2003/001442

申请日：2003-07-21

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun ,  KIM, Se-Woong ,  LEE, Seung-Ju

Inventor： CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun ,  KIM, Se-Woong ,  LEE, Seung-Ju

IPC: A61K31/337

CPC classification number: A61K47/06 ,  A61K9/0019 ,  A61K9/0024 ,  A61K31/337 ,  A61K47/14 ,  A61K47/44

Abstract: The present invention relates to a paclitaxel composition and the preparation methods thereof for the treatment of bladder cancer wherein said paclitaxel composition comprises 4~90% by weight of at least one selected from the monoglycerides, 0.01~90% by weight of at least one oil, 0.01~90% by weight of at least one emulsifier and 0.01~20% by weight of paclitaxel. The composition of the present invention can treat bladder cancer effectively since the composition solubilizes paclitaxel, does not form aggregates, adsorbs well on the bladder wall and penetrates into the muscle layer of the bladder.

Abstract translation: 本发明涉及紫杉醇组合物及其治疗膀胱癌的制备方法，其中所述紫杉醇组合物包含4〜90重量％的选自单酸甘油酯，0.01〜90重量％的至少一种油 ，0.01〜90重量％的至少一种乳化剂和0.01〜20重量％的紫杉醇。 本发明的组合物可以有效治疗膀胱癌，因为组合物溶解紫杉醇，不形成聚集体，在膀胱壁上很好地吸附并渗入膀胱的肌肉层。

公开(公告)号：WO2004009073A1

公开(公告)日：2004-01-29

申请号：PCT/KR2003/001441

申请日：2003-07-21

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun ,  YUK, Soon-Hong

Inventor： CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun ,  YUK, Soon-Hong

IPC: A61K31/245

CPC classification number: A61K9/5078 ,  A61K9/0095 ,  A61K9/5026 ,  A61K9/5031 ,  A61K31/14 ,  A61K31/245 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a new use of octylonium bromide as p-glycoprotein inhibitor to increase cellular uptake of drugs. More particularly, the present invention provides octylonium bromide as a p-glycoprotein inhibitor to increase cellular uptake of drugs such as anticancer drugs by taking octylonium bromide simultaneously with or proceding drug administration.

Abstract translation: 本发明涉及辛基溴化物作为P-糖蛋白抑制剂的新用途，以增加药物的细胞吸收。 更具体地，本发明提供了作为P-糖蛋白抑制剂的辛基溴化铵，以通过同时服用辛基溴或同时给予药物来增加药物如抗癌药物的细胞摄取。

公开(公告)号：WO2003015827A1

公开(公告)日：2003-02-27

申请号：PCT/KR2002/001554

申请日：2002-08-14

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  JAKWANG CO., LTD. ,  KWON, Ick,Chan ,  KIM, In-San ,  JEONG, Seo,Young ,  CHUNG, Hesson ,  CHO, Yong,Woo ,  SON, Yoen,Ju ,  PARK, Chong,Rae ,  SEO, Sang, Bong

Inventor： KWON, Ick,Chan ,  KIM, In-San ,  JEONG, Seo,Young ,  CHUNG, Hesson ,  CHO, Yong,Woo ,  SON, Yoen,Ju ,  PARK, Chong,Rae ,  SEO, Sang, Bong

IPC: A61K47/48

CPC classification number: A61K31/704 ,  A61K47/61 ,  A61K47/6907

Abstract: The present invention relates to an anticancer drug-chitosan complex forming self-aggregates and the preparation method thereof. More precisely, the present invention relates to the anticancer drug-chitosan complex forming self-aggregates in aqueous media composed of a hydrophobic anticancer agent and a hydrophilic chitosan, and the preparation method thereof. The anticancer drug-chitosan complex of the present invention not only works selectively against target tumor tissue but also continues to release the medicine over a long period of time. Besides, the anticancer drug-chitosan complex could have greater amount of drug by adding the anticancer drug into self-aggregates, which is generally limited by chemical bond. Therefore, the anticancer drug-chitosan complex of the present invention can be effectively used for the cancer chemotherapy.

Abstract translation: 本发明涉及形成自聚集体的抗癌药物 - 壳聚糖复合物及其制备方法。 更准确地说，本发明涉及在由疏水性抗癌剂和亲水性壳聚糖组成的水性介质中形成自聚集体的抗癌药物 - 壳聚糖复合物及其制备方法。 本发明的抗癌药物 - 壳聚糖复合物不仅对目标肿瘤组织有选择性的作用，而且还能够长时间地释放药物。 此外，抗癌药物 - 壳聚糖复合物可以通过将抗癌药物加入自聚集体中而具有更大量的药物，其通常受化学键的限制。 因此，本发明的抗癌药物 - 壳聚糖复合物可以有效地用于癌症化疗。

公开(公告)号：WO2006075881A1

公开(公告)日：2006-07-20

申请号：PCT/KR2006/000130

申请日：2006-01-12

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  KWON, Ick Chan ,  JEONG, Seo Young ,  KIM, In-san ,  CHUNG, Hesson ,  SEO, Sang Bong ,  PARK, Jae Hyung ,  KWON, Seunglee ,  KIM, Kwangmyung ,  KIM, Jong-ho

Inventor： KWON, Ick Chan ,  JEONG, Seo Young ,  KIM, In-san ,  CHUNG, Hesson ,  SEO, Sang Bong ,  PARK, Jae Hyung ,  KWON, Seunglee ,  KIM, Kwangmyung ,  KIM, Jong-ho

IPC: A61K9/00

CPC classification number: A61K31/337 ,  A61K9/0019 ,  A61K9/5123 ,  A61K9/5161 ,  A61K47/61

Abstract: Disclosed are a cholanic acid-chitosan complex forming self-aggregates and a preparation method thereof, and more particularly, a cholanic acid-chitosan complex which is composed of hydrophobic cholanic acid and hydrophilic chitosan and forms self-aggregates in an aquatic environment, and a method of preparing the cholanic acid- chitosan complex. The cholanic acid-chitosan complex forms self -aggregates, which prolong the drug release period, enhance the selectivity of the complex for tumor tissue, and greatly increase drug loading content when a drug is incorporated into the self -aggregates, compared to chemical bonding, which limits drug incorporation. Thus, the cholanic acid-chitosan complex is useful for anticancer chemotherapy.

Abstract translation: 公开了形成自聚集体的胆酸 - 壳聚糖复合物及其制备方法，更具体地说，涉及由疏水性胆酸和亲水性壳聚糖构成并在水生环境中形成自聚集体的胆酸 - 壳聚糖复合物， 制备胆酸 - 壳聚糖复合物的方法。 与化学键合相比，胆酸 - 壳聚糖复合物形成自聚集体，其延长药物释放时间，增强复合物对肿瘤组织的选择性，并且当药物掺入自聚集体时大大增加药物负载量， 这限制了药物并入。 因此，胆酸 - 壳聚糖复合物可用于抗癌化疗。

公开(公告)号：WO2004009075A1

公开(公告)日：2004-01-29

申请号：PCT/KR2003/001427

申请日：2003-07-18

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun ,  YUK, Soon-Hong ,  CHOI, Young-Wook ,  PARK, Jae-Hyung ,  CHUNG, Jin-Wook

Inventor： CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun ,  YUK, Soon-Hong ,  CHOI, Young-Wook ,  PARK, Jae-Hyung ,  CHUNG, Jin-Wook

IPC: A61K31/337

CPC classification number: A61K31/337 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/107 ,  A61K45/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44 ,  A61K2300/00

Abstract: The present invention relates to a paclitaxel composition and the preparation methods thereof to solubilize paclitaxel wherein said composition comprises 4~90% by weight of at least one selected from the monoglycerides, 0.01~90% by weight of at least one oil and 0.01~20% by weight of paclitaxel. Also the present invention relates to a paclitaxel composition including emulsifiers and the preparation methods thereof to solubilize paclitaxel wherein said composition comprises 4~90% by weight of at least one selected from the monoglycerides, 0.01~90% by weight of at least one oil, 0.01~90% by weight of at least one emulsifier and 0.01~20% by weight of paclitaxel. The composition of the present invention is an effective paclitaxel delivery system since the composition solubilizes paclitaxel, does not form aggregates after being dispersed in water, adsorbs well on the intestinal wall, and therefore has high bioavailability.

Abstract translation: 本发明涉及紫杉醇组合物及其制备方法，其中所述组合物包含4〜90重量％的选自单酸甘油酯，0.01〜90重量％的至少一种油和0.01〜20重量％的至少一种 紫杉醇的重量％。 本发明还涉及包含乳化剂的紫杉醇组合物及其制备方法来溶解紫杉醇，其中所述组合物包含4〜90重量％的选自单酸甘油酯，0.01〜90重量％的至少一种油的至少一种， 0.01〜90重量％的至少一种乳化剂和0.01〜20重量％的紫杉醇。 本发明的组合物是有效的紫杉醇递送系统，因为组合物溶解紫杉醇，在分散在水中后不形成聚集体，在肠壁上吸附良好，因此具有高的生物利用度。

公开(公告)号：WO2002064115A1

公开(公告)日：2002-08-22

申请号：PCT/KR2002/000205

申请日：2002-02-08

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  CHUNG, Hesson

Inventor： JEONG, Seo-Young ,  KWON, Ick-Chan ,  CHUNG, Hesson

IPC: A61K9/107

CPC classification number: A61K9/0095 ,  A61K9/1075 ,  A61K9/4858

Abstract: The present invention relates to a liquid insulin formulation and the preparation method thereof. More particularly, the present invention relates to a liquid and powder formulations comprising a monoglyceride, an emulsifier, organic solvent, insulin and acidic aqueous solution. The present invention relates to the liquid and powder insulin formulations with a higher encapsulation efficiency of insulin, higher bioavailability upon oral administration with higher patient compliance and the preparation method thereof.

Abstract translation: 本发明涉及一种液体胰岛素制剂及其制备方法。 更具体地说，本发明涉及包含单酸甘油酯，乳化剂，有机溶剂，胰岛素和酸性水溶液的液体和粉末制剂。 本发明涉及具有较高胰岛素包封率的液体和粉末胰岛素制剂，口服给药后具有较高的患者依从性的较高生物利用度及其制备方法。

公开(公告)号：WO2005077336A1

公开(公告)日：2005-08-25

申请号：PCT/KR2005/000378

申请日：2005-02-07

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  LEE, Soo-Yeon ,  ROH, Kyung-Ho

Inventor： CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  LEE, Soo-Yeon ,  ROH, Kyung-Ho

IPC: A61K9/107

CPC classification number: A61K9/006 ,  A61K9/107 ,  A61K9/1274

Abstract: The present invention relates to an emulsion or cubosome composition sterically stabilized by including biocompatible polymers, an emulsion or cubosome formulation including the same composition and the preparation method thereof.

Abstract translation: 本发明涉及通过包括生物相容性聚合物，包含相同组成的乳液或立方体制剂及其制备方法空间稳定的乳剂或立体组合物。

公开(公告)号：WO2004009122A1

公开(公告)日：2004-01-29

申请号：PCT/KR2003/001443

申请日：2003-07-21

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun

Inventor： CHUNG, Hesson ,  JEONG, Seo-Young ,  KWON, Ick-Chan ,  PARK, Yeong-Taek ,  LEE, In-Hyun

IPC: A61K47/44

CPC classification number: A61K9/006 ,  A61K9/0019 ,  A61K9/1075 ,  A61K31/225 ,  A61K47/14 ,  A61K47/44

Abstract: The present invention relates to a novel mucoadhesive composition for solubilization of insoluble drugs; its formulation including pharmaceutical compounds; and the preparation methods thereof wherein said solubilizing composition comprises 4~90% by weight of at least one selected from the monoglycerides and 0.01~90% by weight of at least one oil. The present invention relates to a novel mucoadhesive composition including pharmaceutical compounds; and the preparation methods thereof wherein said solubilizing composition including emulsifiers is composed of 4~90% by weight of at least one selected from the monoglycerides, 0.01~90% by weight, of at least one oil, and 0.01~90% by weight of at least one selected from the emulsifiers. The compositions of the present invention is suitable as drug delivery systems since they exist as mucoadhesive liquid at physiological temperatures even though they exist as liquid or semi-solid at room temperature.

Abstract translation: 本发明涉及一种用于溶解不溶性药物的新型粘膜粘附组合物， 其制剂包括药物化合物; 及其制备方法，其中所述增溶组合物包含4〜90重量％的选自单酸甘油酯和0.01〜90重量％的至少一种油的至少一种。 本发明涉及包含药物化合物的新型粘膜粘附组合物; 及其制备方法，其中所述包含乳化剂的增溶组合物由4〜90重量％的选自单酸甘油酯，0.01〜90重量％，至少1种油和0.01〜90重量％ 选自乳化剂中的至少一种。 本发明的组合物适合作为药物递送系统，因为它们在生理温度下作为粘膜粘附液体存在，即使它们在室温下以液体或半固体形式存在。